<SEC-DOCUMENT>0001683168-20-002063.txt : 20200625
<SEC-HEADER>0001683168-20-002063.hdr.sgml : 20200625
<ACCEPTANCE-DATETIME>20200625161725
ACCESSION NUMBER:		0001683168-20-002063
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200625
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200625
DATE AS OF CHANGE:		20200625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		20989453

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k-062520.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>June 25, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-37487</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: center"><FONT STYLE="font-size: 10pt"><B>13-3632859</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9635 Granite Ridge Drive, Suite 100</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Diego, California</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>92123</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: 858-459-7800 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 96%"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 19%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Trading Symbol</FONT></TD>
    <TD STYLE="width: 51%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Common Stock</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">AEMD</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">The Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02 Results of Operations and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 25, 2020, Aethlon Medical, Inc. (the &ldquo;Registrant&rdquo;)
issued a press release announcing its financial results for the fiscal year ended March 31, 2020. A copy of the press release is
attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information provided in this Item 2.02 of this Current Report
on Form 8-K, including the exhibits, shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that section, nor shall it
be deemed incorporated by reference into any of the Company&rsquo;s filings under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><U>Exhibit No. </U></FONT></TD>
    <TD STYLE="width: 78%; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Description </U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="aethlon_ex9901.htm">Press Release of the Registrant dated June 25, 2020.</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>Aethlon Medical, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Dated: June 25, 2020</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ James B. Frakes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James B. Frakes</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="image_001.jpg" ALT="" STYLE="height: 54pt; width: 144.75pt"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Aethlon
Medical Announces Fiscal Year Financial Results and Provides Corporate Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SAN DIEGO, CA, June 25, 2020 -- Aethlon Medical, Inc. (Nasdaq:
AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases,
today reported financial results for its fiscal year ended March 31, 2020 and provided an update on recent developments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Updates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc. (Company or Aethlon) is continuing the
development of its proprietary Hemopurifier&reg;, which is a first in class therapeutic device designed for the single use depletion
of cancer-promoting exosomes and circulating viruses. The Hemopurifier has previously been designated a Breakthrough Device by
the FDA for the treatment of glycosylated viruses, including Ebola and other hemorrhagic fever viruses, and in late 2018 was additionally
designated as a Breakthrough Device &ldquo;&hellip;for the treatment of individuals with advanced or metastatic cancer who are
either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate
in the development or severity of the disease&hellip;.&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon is currently preparing for the initiation of clinical
trials in patients with advanced and metastatic cancers. The Company is initially focused on the treatment of solid tumors, including
head and neck cancer, gastrointestinal cancers and other cancers. Under an Investigational Device Exemption (IDE) application approved
by FDA in October 2019 the Company is initiating an Early Feasibility Study (EFS &ndash; the device equivalent of a phase 1 study)
in patients with advanced and/or metastatic head and neck cancer at the UPMC Hillman Cancer Center in Pittsburgh, PA. The EFS will
enroll 10-12 subjects and will investigate the combination of the Hemopurifier with standard of care pembrolizumab (Keytruda&reg;)
in the front line setting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 17, 2020, the FDA approved a supplement to the Company&rsquo;s
existing IDE for the use of the Hemopurifier in life threatening viral infections, to allow for the treatment of patients with
SARS-CoV-2/COVID-19 infection. This will allow for up to 40 of these patients to be treated under a New Feasibility Study protocol
at up to 20 clinical sites in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In other news, the Company announced that Thomas L. Taccini
has joined the Aethlon management team as Vice President, Manufacturing and Product Development. Mr. Taccini has over 35 years
of experience in leading teams in engineering, product development, project management, quality systems and regulatory affairs
for multiple different classes of medical devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Results for the Fiscal Year Ended March 31, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company recorded government contract revenue of $650,187
in the fiscal year ended March 31, 2020.&nbsp;&nbsp;This revenue resulted from work performed under the Company&rsquo;s Phase 2
Melanoma Cancer Contract with the National Institutes of Health, or NIH. The Company recorded government contract revenue of $229,625
in the fiscal year ended March 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating expenses for the fiscal year ended March 31, 2020
were approximately $6.58 million, compared to $6.23 million for the fiscal year ended March 31, 2019. This increase of approximately
$350,000, or 6%, in the fiscal year ended March 31, 2020 was due to increases in professional fees of $537,000 and in general and
administrative expense of $595,000, which were partially offset by a decrease of $781,000 in payroll and related expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $537,000 increase in our professional fees in the fiscal
year ended March 21, 2020 was primarily due to a $694,000 increase in our legal fees and a $111,000 increase in our accounting
fees, which were partially offset by decreases of $245,000 in consulting fees. The increase in legal and accounting fees related
to increased activity in our registration statement filings and in intellectual property actions, among other matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $595,000 increase in general and administrative expenses
in the fiscal year ended March 21, 2020 was primarily due to the combination of a $316,000 increase in our clinical trial expenses,
a $198,000 increase in subcontracting and other costs related to our government contracts, and an increase of $87,000 in laboratory
supplies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $781,000 decrease in payroll and related expenses in the
fiscal year ended March 21, 2020 was due to a combination of a decrease in our stock-based compensation of $475,000 and a decrease
of $306,000 in cash-based compensation, primarily due to the termination of consulting and severance payments to our former chief
executive officer and former president.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other expense in the fiscal year ended March 21, 2020 consisted
of a non-cash loss on debt extinguishment, interest expense and a gain on share for warrant exchanges, and in the fiscal year ended
March 21, 2019, consisted of interest expense only. Other expense for the fiscal year ended March 21, 2020 was approximately $450,000,
compared to other expense of approximately $220,000 for the fiscal year ended March 21, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the changes in revenues and expenses noted above,
our net loss before noncontrolling interests increased to approximately $6,380,000 for the fiscal year ended March 31, 2020, from
$6,220,000 for the fiscal year ended March 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At March 31, 2020, we had a cash balance of approximately $9.6
million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2020, we raised additional cash through the sale of
2,685,600 shares of common stock under our ATM facility at an average price of $2.70 per share of net proceeds. The aggregate net
proceeds to us were approximately $7.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The unaudited condensed consolidated balance sheet for March
31, 2020 and the unaudited condensed consolidated statements of operations for the fiscal years ended March 31, 2020 and 2019 follow
at the end of this release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conference Call</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The Company will hold
a conference call today, Thursday, June 25, 2020 at 4:30 p.m. Eastern Time to review financial results and recent corporate developments.
Following management's formal remarks, there will be a question and answer session.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Interested parties can
register for the conference by navigating to http://dpregister.com/10145174.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Please note that registered
participants will receive their dial in number upon registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Interested parties without
internet access or unable to pre-register may dial in by calling: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 35%">PARTICIPANT DIAL IN (TOLL
FREE):</TD>
    <TD STYLE="width: 65%">1-844-836-8741</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>PARTICIPANT INTERNATIONAL
DIAL IN:</TD>
    <TD>1-412-317-5442</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">All callers should ask
for the Aethlon Medical, Inc. conference call. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">A replay of the call will
be available approximately one hour after the end of the call through July 2, 2020. The replay can be accessed via Aethlon Medical&rsquo;s
website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay
conference ID number is 10145174.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Aethlon and the Hemopurifier&reg;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon is focused on addressing unmet needs in global health.
The Aethlon Hemopurifier is a clinical- stage immunotherapeutic device designed to combat cancer and life-threatening viral infections.
In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These tumor derived exosomes also seed the spread of metastases
and inhibit the benefit of leading cancer therapies. The Hemopurifier&reg; is an FDA designated &quot;Breakthrough Device&quot;
related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard
of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease
cancer. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed
with approved therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon also owns 80% of Exosome Sciences, Inc., which is focused
on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information
can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks
and uncertainties. Statements containing words such as &quot;may,&quot; &quot;believe,&quot; &quot;anticipate,&quot; &quot;expect,&quot;
&quot;intend,&quot; &quot;plan,&quot; &quot;project,&quot; &quot;will,&quot; &quot;projections,&quot; &quot;estimate,&quot; &quot;potentially&quot;
or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks
and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These
forward-looking statements are based upon Aethlon&rsquo;s current expectations and involve assumptions that may never materialize
or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company&rsquo;s
ability to enroll patients in and successfully complete trials in the Early Feasibility Studies in head and neck cancer and in
COVID-19 patients, the Company&rsquo;s ability to successfully complete development of its Hemopurifier, and other potential risks.
The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results
to differ materially from those anticipated in forward-looking statements can be found under the caption &quot;Risk Factors&quot;
in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings with the Securities
and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release
speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake
any duty, to update this information to reflect future events or circumstances.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes, CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">858-459-7800 extension 3300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tony Russo, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Russo Partners, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">tony.russo@russopartnersllc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212-845-4251</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Susan Noonan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">S.A. Noonan Communications, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">susan@sanoonan.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212-966-3650</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "O =8# 2(  A$! Q$!_\0
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MG<QL#CZ^E<=2A5I?'&QT0JPG\++-%%%8F@4444 %%%% !1110 4444 %%%%
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M3<V<NCSME[<;X23U0GD?@3^OM7=UX1X?U0Z/KEK? D+&X\P>J'AOT)KW8$,
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MN0\-_%[Q9J7B?2K"YGM6@NKR*&0"  [6<*<'Z&NO^/7_ "(]G_V$D_\ 1<M
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M^BJ "O*_B]X TV?0;CQ%IMJMM?6F'G6% %G0GDD#C<,YW>@(.>,>J5@>//\
MD0M<_P"O&7_T$T >#?"/49-/^(VGJLA2.Z#P2C^\"I('_?04_A7TQ7RQ\.?^
M2A:)_P!?2_UKZGH ^8/BI_R4K6/^NB?^BUKW?X:_\D[T7_KW_J:\(^*G_)2M
M8_ZZ)_Z+6O=_AK_R3O1?^O?^IH$9/Q>\6S>&O"RVUC*T5]J3&*.13AHT ^=@
M?7D#L1NR.E>3_"_P/'XSUV0WI8:;8A7N IP9"<[4SU .#DCL.Q(-:_QYNGD\
M96=MO;RX;%2%/0,SODCZ@+^5=S\#;+[-X#:X(YN[R23..P"KC\U/YT =]8Z?
M9Z9:):6%K#:V\?W8H4"J/7@5-)&DL;1R(KHXPRL,@CT(IU% SPCXO?#JUT-%
M\0:+ (;.239=6Z [8F/1E'92>,= <8Z\:7P*\52R?:/"]T^Y(T-Q:$_PC/SI
MU]6# 8_O>U>B>/K2*]\ ZY%,H95LI)0#_>1=Z_JHKYY^'%^=.^(6B3@$[[H0
M\#_GH#'_ .S4 ?3.N?\ (!U#_KUE_P#037R+;7$UG=175O(8YH7$D;KU5@<@
MC\:^NM<_Y &H_P#7K+_Z":^2M+LCJ.K6=B&VFYG2$-Z;F _K0(]I^%?PQTY=
M'M_$&NVB75S=*);:"4!DCC/W6*]&)!SSTXZ&O65544*H"J!@ #@"D1$BC6.-
M0J( %4#@ =J=0,Y_Q7X,T?Q=I\D%]:QBYV$0W83]Y$V.#GJ1G^$\&OEV>&[T
M;5I(68PW=E.5)4\I(C8X/L17V%7R9XS_ .1XU[_L)7'_ *,:@#ZHTF^75-'L
MM0086[MXY@/0,H;^M6ZQ?!G_ "(^@_\ 8-M__1:UM4 >!ZNV_6KYR,%KB0_^
M/&J=7=90QZY?QG^&YD'/^\:I5]G#X4?//<OZ+I4VM:M!80Y!E;YFQ]Q>I/Y5
M[G:VT-E:Q6L"!(H4"(H[ 5R/PXT'[#IC:I.N)[P?N\_PQ]OS//T KM*^=S#$
M>TJ<JV7YGJX2ER0YGNPHHHKSCL"BBB@"IJNIVNC:7<ZE>R".WMHS([>P[#U)
MZ =R:^3_ !#K=SXCUZ\U>[XENI"VT=$7HJ_@H _"O4_CKXJ??;^%[5R$P+B[
M(/WO[B=?JQ!']WTKQN@ HHHH Z;X?^*W\(>*K>^9C]DE_<W:^L9/)Z'E3AN.
MN,=Z]&\>:&NF:Q]LM@#:7V9$*] W\0_7(^OM7B=>U?#S5$\;^!;CPK=N/[1T
MQ0]HS$9:,<+[_*?E/' 9>]=>#K^QJIO9[G/B*7M(:;G,T4Z2-XI&CD4JZ$JR
MD8((ZBFU]4>*%%%%, KT7X4$[=57)P/)('_?=>=5Z-\*$8)JCD?*3$!]1O\
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M3X%Q6MPEWXFNX[K8<BSMB=A]-SG!/T 'U/2O7(HHX(DABC6..-0J(@P% X
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M1J%B\/1Q\R$]F'^<5PS*58JP((."#VKT2N<UK0YYKWS[.(.)!EQN PWX^O\
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MXXRI1HNDU9]/)',\/&I4YT]"T %4*H  & !VI:**\T[0HHHH **** "BBB@
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<'>3N=$81C\*L%%%%04%%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
